
FDA-Approved Epi-On CXL for Keratoconus
FDA-Approved Epi-On CXL for Keratoconus For patients with keratoconus, corneal cross-linking has long been one of the most effective tools for stopping disease progression. An FDA-approved significant advancement in how that treatment is delivered was approved in October 2025, a...
View More








